{"url_path":"/sec/goss/8-k/2026-07-15/item-5-03","section_key":"item-5-03","section_title":"Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1728117/0001728117-26-000061-index.html","accession_number":"0001728117-26-000061","cik":"0001728117","ticker":"GOSS","issuer_name":"Gossamer Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1728117/0001728117-26-000061-index.html","primary_entity_key":"0001728117","primary_entity_name":"Gossamer Bio, Inc."},"word_count":192,"has_tables":true,"body_markdown":"Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.\n\nOn July 14, 2026, following approval by the Company's stockholders at the Special Meeting, the Company filed a certificate of amendment (the “Charter Amendment”) to the Amended and Restated Certificate of Incorporation of the Company (the “Charter”) with the Secretary of State of the State of Delaware to increase the number of authorized shares of its Common Stock from 700,000,000 to 4,000,000,000 in order to support, among other things, the additional share issuances of Common Stock issuable upon conversion of the Company's newly issued 7.50% Convertible Senior Secured First Lien Notes due 2030 (the “New Convertible Notes”) and exercise of the Company’s newly issued warrants to purchase shares of Common Stock (the “Purchase Warrants”), each issued as part of the Exchange Offer, and under the Restated Plan. The Charter Amendment became effective upon filing.\n\nThe foregoing description of the Charter Amendment is not complete and is subject to, and qualified in its entirety by, the complete text of the Charter Amendment, which is filed as Exhibit 3.1 to this Current Report on Form 8-K, and incorporated herein by reference."}